Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has emerged as a powerful tool for weight management, with clinical studies demonstrating that patients can lose between 15-22% of their starting body weight when combined with lifestyle modifications. Understanding realistic weight loss outcomes helps patients set achievable goals and stay motivated throughout their treatment journey. PlexusDx provides access to compounded semaglutide therapy tailored to individual metabolism and genetic factors.

Average Weight Loss on Semaglutide Therapy

Clinical trial data from the STEP program demonstrated that participants taking semaglutide once weekly achieved average weight loss of approximately 15-22% of baseline body weight over 68 weeks of treatment. This translates to roughly 15-25 pounds for someone starting at 200 pounds, though individual results can range significantly higher. The medication works by slowing gastric emptying, increasing satiety signals to the brain, and helping regulate blood sugar levels—three mechanisms that work together to reduce overall calorie intake.

Weight loss typically occurs in phases during semaglutide treatment. Most patients experience initial water weight loss in the first 2-4 weeks, followed by steady fat loss over subsequent months. By month three, many patients report noticeable changes in appetite control and eating patterns. The most significant weight loss often occurs between weeks 12-24 as the body adjusts to the medication and lifestyle changes become more consistent.

Factors That Influence Individual Weight Loss Results

Not all patients lose weight at the same rate on semaglutide, and genetic factors play a substantial role in treatment response. Some people carry genetic variations that make their bodies more responsive to GLP-1 therapy, while others may require higher doses or longer treatment periods to see comparable results. The PlexusDx Precision Peptide Genetic Test analyzes key variants in the GLP1R gene and other metabolic pathways to predict individual responsiveness and optimize therapy from the start.

Beyond genetics, weight loss outcomes depend on baseline body weight, age, metabolic health, physical activity level, and dietary adherence. Patients who combine semaglutide with consistent exercise and balanced nutrition typically lose more weight than those relying on medication alone. Sleep quality, stress management, and underlying conditions like thyroid dysfunction can also affect how quickly someone loses weight. PlexusDx providers consider all these factors when designing personalized treatment protocols.

Realistic Expectations vs. Marketing Claims

Many direct-to-consumer weight loss ads exaggerate results or cherry-pick extreme outcomes, creating unrealistic expectations. While some patients do lose 30% or more of their body weight, this is not typical. A reasonable expectation for most people starting semaglutide is 10-15% weight loss in the first six months, with continued gradual loss over months 7-12 if treatment is maintained. Setting modest, achievable goals reduces disappointment and increases the likelihood of long-term success.

Weight loss plateaus are normal and expected during extended semaglutide therapy. Many patients experience rapid loss in months 1-4, then slower loss in months 5-8, followed by a maintenance phase. This plateau does not mean the medication has stopped working—it often reflects the body reaching a new, healthier baseline weight. Some patients benefit from dose adjustments, medication changes, or intensified lifestyle interventions to break through plateaus.

PlexusDx Compounded Semaglutide Pricing & Access

PlexusDx offers compounded semaglutide injections starting at $149 per month from licensed 503A compounding pharmacies, with no insurance requirement and no membership fees. Your dose may need to go up. Your price won't. This flat-rate pricing model removes financial barriers to dose optimization and allows providers to adjust treatment upward based on clinical response without increased out-of-pocket costs. HSA and FSA accounts are accepted for added flexibility.

PlexusDx serves all 50 states and can combine semaglutide with genetic testing through the Precision Peptide Genetic Test ($99 add-on after the first month) to identify personalized peptide pathways and predict medication responsiveness. This data-driven approach helps match patients with the most effective therapy and appropriate dosing strategy from day one, maximizing weight loss potential while minimizing trial-and-error.

Timeline: When to Expect Weight Loss on Semaglutide

Week 1-2: Most patients notice appetite suppression and reduced food cravings within days of starting semaglutide. Some mild side effects like nausea or constipation may appear but typically resolve within a few days as the body adjusts. Weight changes in this phase are usually minimal and reflect water loss rather than fat loss.

Month 1-3: Steady fat loss begins as appetite control deepens and eating patterns shift. Patients often report eating smaller portions naturally, without feeling deprived. Average weight loss during this phase is 5-8 pounds for most people, though faster loss is possible with strict dietary adherence. Month 3-6: Weight loss continues at a steady pace, with many patients reaching 10-15% of baseline body weight loss by the end of month six. Energy levels often improve as weight decreases and metabolic health improves.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight should I expect to lose in the first month on semaglutide?

Most patients lose 3-8 pounds in the first month, primarily through appetite suppression and reduced calorie intake. Initial weight loss often includes water loss. Realistic expectations for month one range from 2-5 pounds of actual fat loss for most people. PlexusDx providers adjust dosing based on individual response to optimize results.

What clinical trial data supports semaglutide's weight loss claims?

The STEP program (Semaglutide Treatment Effect in People with obesity) demonstrated 15-22% average weight loss over 68 weeks in overweight or obese adults. Participants taking the highest dose (2.4 mg weekly) lost significantly more weight than those on lower doses or placebo. These results were sustained even after stopping the medication, suggesting lasting metabolic benefits.

Is weight loss from semaglutide permanent, or does it come back after stopping?

Weight loss achieved on semaglutide is not automatically permanent after stopping. Studies show that some weight regain occurs in patients who discontinue therapy without maintaining the lifestyle changes adopted during treatment. PlexusDx recommends continued therapy combined with sustained nutrition and exercise modifications for long-term success.

Can genetics predict how much weight I'll lose on semaglutide?

Yes. The PlexusDx Precision Peptide Genetic Test identifies variants in the GLP1R, GIPR, FTO, and MC4R genes that influence individual medication responsiveness and weight loss potential. Patients with favorable genetic profiles often see faster, more substantial weight loss. This data helps PlexusDx tailor dosing and therapy selection for maximum effectiveness.

Why is PlexusDx semaglutide more affordable than brand-name Wegovy?

PlexusDx offers compounded semaglutide from licensed 503A pharmacies at $149/month with flat pricing regardless of dose. Brand-name medications carry higher markups and insurance costs. PlexusDx serves all 50 states without insurance requirements, making therapy accessible and affordable for more patients. HSA/FSA eligibility provides additional cost savings.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves